Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians

Pharmacogenetics and Genomics

Volumn 19, Issue 10, 2009, Pages 760-769

  Boeckmann, Lars ^a   Schirmer, Markus ^a   Rosenberger, Albert ^a   Struever, Diana ^a   Thoms, Kai Martin ^a   Gutzmer, Ralf ^b   Has, Cristina ^c   Kunz, Manfred ^d   Kuschal, Christiane ^a   Laspe, Petra ^a   Schoen, Michael P ^a   Brockmoeller, Juergen ^a   Emmert, Steffen ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Dacarbazine; Genetic variants; Melanoma; MGMT; Mismatch repair; Promoter methylation; Side effects; Temozolomide; Treatment efficacy

Indexed keywords

DACARBAZINE; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN MSH2; TEMOZOLOMIDE;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA REPAIR; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC VARIABILITY; HEMATOLOGIC DISEASE; HISTOPATHOLOGIC SKIN REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MISMATCH REPAIR; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DNA REPAIR; DNA, NEOPLASM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR CELLS, CULTURED;

EID: 70349576593     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283307cd9     Document Type: Article

References (46)

1. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 1996; 34:839-847.
2. Keilholz U, Kaufmann R, Tilgen W. Systemic treatment of advanced melanoma. Onkologe 2001; 7:61-70.
3. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
4. Brown CK, Kirkwood JM. Medical management of melanoma. Surg Clin North Am 2003; 83:283-322.
5. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40:1825-1836.
6. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008; 26:2299-2304.
7. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193-201.
8. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
9. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19:21-34.
10. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007; 12:1114-1123. (Pubitemid 350007023)
11. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007; 6:1079-1099.
12. Karran P, Macpherson P, Ceccotti S, Dogliotti E, Griffin S, Bignami M. O6-methylguanine residues elicit DNA repair synthesis by human cell extracts. J Biol Chem 1993; 268:15878-15886.
13. Alvino E, Castiglia D, Caporali S, Pepponi R, Caporaso P, Lacal PM, et al. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. Int J Oncol 2006; 29:785-797.
14. Roos W, Baumgartner M, Kaina B. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 2004; 23:359-367.
15. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007; 13:2038-2045.
16. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16:3851-3857.
17. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006; 106:1759-1765.
18. Nagane M, Kobayashi K, Ohnishi A, Shimizu S, Shiokawa Y. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol 2007; 37:897-906.
19. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846-5852.
20. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23:35-61.
21. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001; 22:1931-1937.
22. Hill CE, Wickliffe JK, Wolfe KJ, Kinslow CJ, Lopez MS, bdel-Rahman SZ. The L84F and the I143V polymorphisms in the O6-methylguanine-DNA- methyltransferase (MGMT) gene increase human sensitivity to the genotoxic effects of the tobacco-specific nitrosamine carcinogen NNK. Pharmacogenet Genomics 2005; 15:571-578.
23. Castiglia D, Pagani E, Alvino E, Vernole P, Marra G, Cannavo E, et al. Biallelic somatic inactivation of the mismatch repair gene MLH1 in a primary skin melanoma. Genes Chromosomes Cancer 2003; 37:165-175.
24. World Health Organization. Handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization; 1979. WHO publication no 48.
25. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284:3043-3045.
26. Den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001; 109:121-124.
27. Lai JC, Cheng YW, Goan YG, Chang JT, Wu TC, Chen CY, et al. Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53. DNA Repair (Amst) 2008; 7:1352-1363.
28. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001; 61:900-902.
29. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998; 95:6870-6875.
30. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14:280-290.
31. Anda T, Shabani HK, Tsunoda K, Tokunaga Y, Kaminogo M, Shibata S, et al. Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 2003; 25:241-248.
32. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de TN, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
33. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350-1354.
34. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10:1871-1874.
35. Kohya N, Miyazaki K, Matsukura S, Yakushiji H, Kitajima Y, Kitahara K, et al. Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol 2002; 9:371-379.
36. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007; 13:806-815.
37. Clemons MJ, Bibby MC, El TH, Forster G, Kelly J, Banerjee S, et al. Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours. Br J Cancer 2002; 86:1797-1802.
38. Wang Y, Kato T, Ayaki H, Ishizaki K, Tano K, Mitra S, et al. Correlation between DNA methylation and expression of O6-methylguanine-DNA methyltransferase gene in cultured human tumor cells. Mutat Res 1992; 273:221-230.
39. Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005; 23:9351-9358.
40. Brabender J, Usadel H, Metzger R, Schneider PM, Park J, Salonga D, et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res 2003; 9:223-227.
41. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-2054.
42. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, et al. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 2004; 95:962-968.
43. Mao G, Pan Y, Gu L. Evidence that a mutation in the MLH1 30-untranslated region confers a mutator phenotype and mismatch repair deficiency in patients with relapsed leukemia. J Biol Chem 2008; 283:3211-3216.
44. Shen H, Sturgis EM, Khan SG, Qiao Y, Shahlavi T, Eicher SA, et al. An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Res 2001; 61:3321-3325.
45. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004; 25:729-734.
46. Khan SG, Muniz-Medina V, Shahlavi T, Baker CC, Inui H, Ueda T, et al. The human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function. Nucleic Acids Res 2002; 30:3624-3631.